SINGAPORE – Troubled private cord blood bank Cordlife will have its suspension extended for up to three months till Sept 15 as the company needs more time to validate its cord blood processing system.that was due to end on June 15. During the suspension period, the cord blood banking company had to cease collecting, testing, processing and/or storing any new cord blood and human tissues.
“Additional time will also be needed to assess the validation data, approve the outcome of the validation, review and approve the SOPs , and conduct staff training and competency assessments, and MOH has assessed that the completion of all requirements will take around three months from June 15, 2024,” said the company.
Cordlife also said in the same bourse filing on May 28 that it had applied on May 15 to stop providing services relating to haematopoietic stem cells under its human tissue banking service, and for now will be focusing only on the provision of services relating to the banking of ocular or eye tissue.
On the same day, the company also applied to discontinue its clinical laboratory service licence from May 20, 2024.